Summit Therapeutics Inc (NASDAQ: SMMT) kicked off on Monday, up 4.61% from the previous trading day, before settling in for the closing price of $21.26. Over the past 52 weeks, SMMT has traded in a range of $1.64-$33.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -28.65%. While this was happening, its average annual earnings per share was recorded 72.30%. With a float of $110.95 million, this company’s outstanding shares have now reached $701.66 million.
Considering the fact that the conglomerate employs 105 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 632.34%, operating margin of 52384.26%, and the pretax margin is 68873.19%.
Summit Therapeutics Inc (SMMT) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Summit Therapeutics Inc is 84.68%, while institutional ownership is 10.18%. The most recent insider transaction that took place on Mar 27 ’24, was worth 201,874. In this transaction Chief Executive Officer of this company bought 54,321 shares at a rate of $3.72, taking the stock ownership to the 24,923,800 shares. Before that another transaction happened on Mar 26 ’24, when Company’s Chief Executive Officer bought 30,000 for $3.75, making the entire transaction worth $112,500. This insider now owns 30,000 shares in total.
Summit Therapeutics Inc (SMMT) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 72.30% per share during the next fiscal year.
Summit Therapeutics Inc (NASDAQ: SMMT) Trading Performance Indicators
Take a look at Summit Therapeutics Inc’s (SMMT) current performance indicators. Last quarter, stock had a quick ratio of 2.35.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.23, a number that is poised to hit -0.07 in the next quarter and is forecasted to reach -0.30 in one year’s time.
Technical Analysis of Summit Therapeutics Inc (SMMT)
Compared to the last year’s volume of 3.68 million, its volume of 1.96 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 31.55%. Additionally, its Average True Range was 1.82.
During the past 100 days, Summit Therapeutics Inc’s (SMMT) raw stochastic average was set at 57.03%, which indicates a significant decrease from 63.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.11% in the past 14 days, which was lower than the 116.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.43, while its 200-day Moving Average is $9.30. Nevertheless, the first resistance level for the watch stands at $23.01 in the near term. At $23.77, the stock is likely to face the second major resistance level. The third major resistance level sits at $24.65. If the price goes on to break the first support level at $21.37, it is likely to go to the next support level at $20.49. Should the price break the second support level, the third support level stands at $19.73.
Summit Therapeutics Inc (NASDAQ: SMMT) Key Stats
The company with the Market Capitalisation of 16.11 billion has total of 701,980K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -614,930 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -60,390 K.
